BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL
87 results:

  • 1. Recent development of VEGFR small molecule inhibitors as anticancer agents: A patent review (2021-2023).
    Zeng J; Deng Q; Chen Z; Yan S; Dong Q; Zhang Y; Cui Y; Li L; He Y; Shi J
    Bioorg Chem; 2024 May; 146():107278. PubMed ID: 38484586
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Targeted drug-loaded PLGA-pcl microspheres for specific and localized treatment of triple negative breast cancer.
    Nwazojie CC; Obayemi JD; Salifu AA; Borbor-Sawyer SM; Uzonwanne VO; Onyekanne CE; Akpan UM; Onwudiwe KC; Oparah JC; Odusanya OS; Soboyejo WO
    J Mater Sci Mater Med; 2023 Aug; 34(8):41. PubMed ID: 37530973
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. ZNF692 promote proliferation through transcriptional repression of essential genes in clear cell renal carcinoma.
    Wang H; Zhao J; He H; Xie X; Dai J; Xu D; Huang X
    Biochem Biophys Res Commun; 2023 Sep; 671():255-262. PubMed ID: 37307709
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Natural History of Pancreatic Cystic Lesions in Liver Transplant Recipients: A Systematic Review and Meta-analysis.
    Canakis A; Vittal A; Deliwala S; Twery B; Canakis J; Patel P; Chahal P
    Pancreas; 2022 Oct; 51(9):1160-1166. PubMed ID: 37078940
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
    Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
    Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Oncological Outcomes of Patients with Non-Clear Cell Renal Cell Cancers: Subtypes of Unclassified and Translocation Renal Cell Cancers.
    Gokalp F; Celik S; Sozen TS; Ozen AH; Aslan G; Izol V; Baltaci S; Muezzinoglu T; Akdogan B; Suer E; Tinay I
    Urol J; 2022 Dec; 20(1):29-33. PubMed ID: 35892147
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
    Passi I; Billowria K; Kumar B; Chawla PA
    Anticancer Agents Med Chem; 2023; 23(5):562-570. PubMed ID: 35718972
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy.
    Liu S; Feng C; Liu C; Wang Z
    Cancer Med; 2021 Dec; 10(24):8909-8923. PubMed ID: 34779154
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
    Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
    Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Pazopanib-induced chylothorax in a patient with renal cell carcinoma.
    Koylu B; Tekin F; Aktas BY; Kilickap S; Koksal D
    Anticancer Drugs; 2022 Jan; 33(1):e555-e557. PubMed ID: 34387587
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas.
    Dumond A; Montemagno C; Vial V; Grépin R; Pagès G
    Cells; 2021 May; 10(5):. PubMed ID: 34067671
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma.
    Gudbrandsdottir G; Aarstad HH; Hjelle KM; Førde K; Reisæter L; Bostad L; Aarstad HJ; Beisland C
    Cytokine; 2021 Aug; 144():155586. PubMed ID: 34058568
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Keratinocyte Cancer Mortality in kidney Transplant Recipients.
    Shao EX; Betz-Stablein B; Khosrotehrani K; Campbell S; Isbel N; Green AC
    Transplantation; 2022 May; 106(5):1078-1083. PubMed ID: 34049361
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with kidney Cancer Treated with Lenvatinib and Pembrolizumab.
    Lee CH; DiNatale RG; Chowell D; Krishna C; Makarov V; Valero C; Vuong L; Lee M; Weiss K; Hoen D; Morris L; Reznik E; Murray S; Kotecha R; Voss MH; Carlo MI; Feldman D; Sachdev P; Adachi Y; Minoshima Y; Matsui J; Funahashi Y; Nomoto K; Hakimi AA; Motzer RJ; Chan TA
    Mol Cancer Res; 2021 Sep; 19(9):1510-1521. PubMed ID: 34039647
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Reactive oxygen species and glutathione dual responsive nanoparticles for enhanced prostate cancer therapy.
    Zhang L; Zhang S; Li M; Li Y; Xiong H; Jiang D; Li L; Huang H; Kang Y; Pang J
    Mater Sci Eng C Mater Biol Appl; 2021 Apr; 123():111956. PubMed ID: 33812584
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients.
    Fernandes FG; Silveira HCS; Júnior JNA; da Silveira RA; Zucca LE; Cárcano FM; Sanches AON; Neder L; Scapulatempo-Neto C; Serrano SV; Jonasch E; Reis RM; Evangelista AF
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668731
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Collagenase IV and clusterin-modified polycaprolactone-polyethylene glycol nanoparticles for penetrating dense tumor tissues.
    Huang HY; Chen LQ; Sun W; Du HH; Dong S; Ahmed AMQ; Cao D; Cui JH; Zhang Y; Cao QR
    Theranostics; 2021; 11(2):906-924. PubMed ID: 33391512
    [No Abstract]    [Full Text] [Related]  

  • 18. The effect of serum uric acid levels on the long-term prognosis of patients with non-ST-elevation myocardial infarction.
    Kuźma Ł; Kulikowska A; Kurasz A; Niwińska MM; Zalewska-Adamiec M; Dobrzycki S; Bachórzewska-Gajewska H
    Adv Clin Exp Med; 2020 Nov; 29(11):1255-1263. PubMed ID: 33269811
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Analysis of the concordance of 20 immunohistochemical tissue markers in metastasectomy lesions in patients with metastatic renal cell carcinoma: A retrospective study using tissue microarray.
    Kim SH; Park WS; Park EY; Joo J; Chung J
    Investig Clin Urol; 2020 Jul; 61(4):372-381. PubMed ID: 32665993
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prognostic Implication of Body Mass Index on Survival Outcomes in Surgically Treated Nonmetastatic Renal Cell Carcinoma: A Single-Institutional Retrospective Analysis of a Large Cohort.
    Seon DY; Kwak C; Kim HH; Ku JH; Kim HS
    Ann Surg Oncol; 2020 Jul; 27(7):2459-2467. PubMed ID: 32246312
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.